Significant challenges face the sector, including falling R&D productivity coupled with increasing generic competition and parallel imports, a reduction in government healthcare budgets, closer regulatory and investor scrutiny, and an increasing focus on drug safety. In addition, fewer drugs are reaching blockbuster status to support company growth, which places an even greater emphasis on patent protection. This means that drug pipelines are increasingly reliant on product / company acquisitions, licensing and collaborations to maintain earnings and reduce portfolio risks.
Our experience includes:
- Bayer in litigation involving patents relating to Bayer’s female oral contraceptive products in the UK, Germany and the Netherlands
- Eli Lilly in patent revocation proceedings involving patents relating to olanzapine
- R-Pharm on the acquisition of a German production plant from Pfizer
- GlaxoSmithKline on the successful representation before the French Supreme Court in cases involving the Hepatitis B vaccine.